Qianhai Health Holdings Limited (0911.HK)
HKD 0.23
(4.55%)
HKD 0.23
(4.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -50.22 Million HKD | 80.74% |
| 2022 | -231.23 Million HKD | -30738.86% |
| 2021 | 2.05 Million HKD | -110.49% |
| 2020 | 5.63 Million HKD | -75.79% |
| 2019 | 31.95 Million HKD | 468.96% |
| 2018 | -11.73 Million HKD | -67.04% |
| 2017 | -19.84 Million HKD | 103.17% |
| 2016 | -529.65 Million HKD | -189.22% |
| 2015 | -350.18 Million HKD | -176.55% |
| 2014 | 260.88 Million HKD | 47.92% |
| 2013 | 165.93 Million HKD | 159.48% |
| 2012 | 79.12 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 8.33 Million HKD | 101.27% |
| 2024 Q1 | 8.33 Million HKD | -86.26% |
| 2023 Q3 | 30.26 Million HKD | 127.27% |
| 2023 Q1 | -55.49 Million HKD | 69.3% |
| 2023 FY | - HKD | 80.74% |
| 2023 Q4 | 62.24 Million HKD | 105.64% |
| 2023 Q2 | -110.99 Million HKD | -100.0% |
| 2022 Q4 | -180.76 Million HKD | -99.22% |
| 2022 Q3 | -90.73 Million HKD | -571.36% |
| 2022 Q1 | 9.62 Million HKD | 66.29% |
| 2022 FY | - HKD | -30738.86% |
| 2022 Q2 | 19.25 Million HKD | 100.0% |
| 2021 Q4 | 5.78 Million HKD | 168.4% |
| 2021 FY | - HKD | -110.49% |
| 2021 Q1 | 1.29 Million HKD | -84.02% |
| 2021 Q2 | -19.4 Million HKD | -1596.88% |
| 2021 Q3 | -8.46 Million HKD | 56.4% |
| 2020 Q1 | 5.61 Million HKD | -58.71% |
| 2020 Q2 | 11.22 Million HKD | 100.0% |
| 2020 Q3 | -3.38 Million HKD | -130.14% |
| 2020 Q4 | 8.11 Million HKD | 339.75% |
| 2020 FY | - HKD | -75.79% |
| 2019 Q4 | 13.59 Million HKD | 106.55% |
| 2019 Q2 | -399 Thousand HKD | -101.01% |
| 2019 Q1 | -198.5 Thousand HKD | 98.88% |
| 2019 FY | - HKD | 468.96% |
| 2019 Q3 | 6.58 Million HKD | 1749.5% |
| 2018 FY | - HKD | -67.04% |
| 2018 Q4 | -17.78 Million HKD | 0.0% |
| 2018 Q3 | -17.78 Million HKD | -316.1% |
| 2018 Q2 | -4.27 Million HKD | 0.0% |
| 2018 Q1 | -4.27 Million HKD | 37.19% |
| 2017 Q1 | -3.12 Million HKD | 98.37% |
| 2017 FY | - HKD | 103.17% |
| 2017 Q2 | -3.12 Million HKD | 0.0% |
| 2017 Q4 | -6.8 Million HKD | 0.0% |
| 2017 Q3 | -6.8 Million HKD | -118.06% |
| 2016 Q4 | -190.85 Million HKD | 0.0% |
| 2016 Q3 | -190.85 Million HKD | -425.02% |
| 2016 Q2 | -36.35 Million HKD | 0.0% |
| 2016 Q1 | -36.35 Million HKD | 90.71% |
| 2016 FY | - HKD | -189.22% |
| 2015 Q2 | 240.19 Million HKD | 0.0% |
| 2015 Q3 | -391.41 Million HKD | -262.95% |
| 2015 FY | - HKD | -176.55% |
| 2015 Q1 | 240.19 Million HKD | 4508.59% |
| 2015 Q4 | -391.41 Million HKD | 0.0% |
| 2014 Q3 | 5.21 Million HKD | -95.84% |
| 2014 Q1 | 125.23 Million HKD | 580.46% |
| 2014 FY | - HKD | 47.92% |
| 2014 Q4 | 5.21 Million HKD | 0.0% |
| 2014 Q2 | 125.23 Million HKD | 0.0% |
| 2013 Q2 | 60.49 Million HKD | 0.0% |
| 2013 Q4 | 18.4 Million HKD | 0.0% |
| 2013 Q3 | 18.4 Million HKD | -69.58% |
| 2013 Q1 | 60.49 Million HKD | 45.84% |
| 2013 FY | - HKD | 159.48% |
| 2012 FY | - HKD | 0.0% |
| 2012 Q4 | 41.48 Million HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 133.397% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 101.693% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 61.219% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 144.139% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 145.738% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 112.006% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 165.545% |
| PuraPharm Corporation Limited | -26.16 Million HKD | -91.941% |
| SSY Group Limited | 2.11 Billion HKD | 102.375% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 124.575% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 111.683% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 100.326% |